Acorda Therapeutics, Inc.
http://www.acorda.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Acorda Therapeutics, Inc.
Sanofi Secures World First Approval For Dupixent In COPD With EU Nod
The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.
Dengue Swells As US Vaccine Prospects Recede
Sanofi’s voluntary Dengvaxia withdrawal due to low demand leaves the US with no dengue vaccine, even as Puerto Rico declares a public health emergency and global cases rise.
Amid Growing Pandemic Fears, Moderna Gets BARDA Funding For Flu Program
The biotech got a $176m award for its pandemic influenza vaccine program through BARDA’s Rapid Response Partnership Vehicle.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Pulmonary
- Other Names / Subsidiaries
-
- Neuronex, Inc.
- Civitas Therapeutics
- Biotie Therapies Corp.
- Elbion GmbH
- Synosia Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice